Scholarlink

Background <p>Systemic lupus erythematosus (SLE) is an autoimmune disease in which disruptions in lipid metabolism contribute to immune dysregulation, inflammation, and organ damage. This study aims to elucidate the role of hepatic asialoglycoprotein receptor 1 (ASGR1) in lipid metabolism dysregulation in lupus nephritis, and to investigate the therapeutic potential of mesenchymal stromal cells (MSCs) in restoring lipid homeostasis via ASGR1 modulation.</p> Method <p>A high-fat diet (HFD)-fed MRL/<i>lpr</i> lupus mouse model was used to assess the impact of lipid dysregulation on lupus pathology. ASGR1 expression and cholesterol metabolism-related genes were evaluated using molecular and histological analyses. Liver-specific <i>Asgr1</i> knockdown was achieved using adeno-associated virus. The therapeutic effects of MSCs were evaluated both in vivo and in vitro, with a focus on ASGR1 regulation and downstream metabolic signaling.</p> Results <p>In MRL/<i>lpr</i> mice, HFD exacerbated lipid accumulation, renal injury, and immune imbalance. ASGR1 expression was significantly upregulated in the liver, leading to suppressed cholesterol efflux and enhanced lipid synthesis. <i>Asgr1</i> knockdown ameliorated these metabolic disturbances. MSCs treatment reduced ASGR1 expression, restored lipid homeostasis, and improved lupus phenotypes by modulating mTOR, LXRα, and AMPK pathways. Overexpression of <i>Asgr1</i> reversed the protective effects of MSCs in vitro.</p> Conclusions <p>Lipid metabolism dysregulation contributes to SLE pathogenesis through ASGR1-mediated pathways. Targeting ASGR1, particularly via MSCs therapy, offers a promising strategy to restore metabolic balance and attenuate disease severity in lupus nephritis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Allogeneic mesenchymal stromal cells ameliorate lupus nephritis by regulating lipid metabolism via ASGR1

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月10日

查看全文
  • Yujiao Wang,
  • Ling Zhao,
  • Simin Guo,
  • Yirui Shi,
  • Yue Zhang,
  • Xiaojuan Han,
  • Xiaojun Tang,
  • Genhong Yao,
  • Weiwei Chen,
  • Lingyun Sun

摘要

Background

Systemic lupus erythematosus (SLE) is an autoimmune disease in which disruptions in lipid metabolism contribute to immune dysregulation, inflammation, and organ damage. This study aims to elucidate the role of hepatic asialoglycoprotein receptor 1 (ASGR1) in lipid metabolism dysregulation in lupus nephritis, and to investigate the therapeutic potential of mesenchymal stromal cells (MSCs) in restoring lipid homeostasis via ASGR1 modulation.

Method

A high-fat diet (HFD)-fed MRL/lpr lupus mouse model was used to assess the impact of lipid dysregulation on lupus pathology. ASGR1 expression and cholesterol metabolism-related genes were evaluated using molecular and histological analyses. Liver-specific Asgr1 knockdown was achieved using adeno-associated virus. The therapeutic effects of MSCs were evaluated both in vivo and in vitro, with a focus on ASGR1 regulation and downstream metabolic signaling.

Results

In MRL/lpr mice, HFD exacerbated lipid accumulation, renal injury, and immune imbalance. ASGR1 expression was significantly upregulated in the liver, leading to suppressed cholesterol efflux and enhanced lipid synthesis. Asgr1 knockdown ameliorated these metabolic disturbances. MSCs treatment reduced ASGR1 expression, restored lipid homeostasis, and improved lupus phenotypes by modulating mTOR, LXRα, and AMPK pathways. Overexpression of Asgr1 reversed the protective effects of MSCs in vitro.

Conclusions

Lipid metabolism dysregulation contributes to SLE pathogenesis through ASGR1-mediated pathways. Targeting ASGR1, particularly via MSCs therapy, offers a promising strategy to restore metabolic balance and attenuate disease severity in lupus nephritis.